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Toward Improved Understanding of a
Potential Association between Isotretinoin
and Inflammatory Bowel Disease
Alisa N. Femia1 and Ruth Ann Vleugels1
Isotretinoin is a widely prescribed medication for nodulocystic acne. Existing
literature is conflicting regarding an association between isotretinoin and inflam-
matory bowel disease. In this issue, Alhusayen et al. report findings from a 12-year
observational study exploring a possible association, and they conclude that acne
itself may be responsible for an apparent correlation.
Journal of Investigative Dermatology (2013) 133, 866–868. doi:10.1038/jid.2012.428
Background and significance
Isotretinoin is the gold-standard treat-
ment for recalcitrant, nodulocystic acne,
and is the only Food and Drug Admin-
istration (FDA)-approved medication for
this indication. Currently, no other treat-
ment approaches the efficacy and sus-
tained response of isotretinoin.
Recently, isotretinoin has received
attention for a potential association with
inflammatory bowel disease (IBD). Evi-
dence regarding this association is con-
flicting, and no randomized controlled
trials have as yet addressed the possibility.
Establishing an association might appro-
priately limit its use, whereas decreased
use of the drug on the basis of an
unfounded association would contribute
to unnecessary scarring and disfigurement
for patients with nodulocystic acne.
In this issue, Alhusayen et al. (2013)
describe a comprehensive, 12-year
population-based observational study
that addressed the possible association
between isotretinoin and IBD. Primary
analyses revealed that there was no asso-
ciation. Prespecified secondary analyses
suggested that there was an association
between IBD and acne, rather than
between IBD and isotretinoin.
Previous evidence linking isotretinoin
and IBD has been conflicting
Fitting the findings of Alhusayen et al.
into the existing literature requires
complex analysis. Isotretinoin was intro-
duced to the market under the brand
name Accutane by Hoffmann–LaRoche
(Nutley, NJ) in 1982. Risk of IBD has
long been listed as a potential side effect
in the Physicians Desk Reference, and
the first case of a potential association
was reported in 1986 (Brodin, 1986).
Causality could not be determined, and
although caution was advised when pre-
scribing isotretinoin to those with bowel
disorders, isotretinoin was not contra-
indicated in this patient population
(Brodin, 1986). Subsequently, additional
case reports supported an association. In
2007, this issue gained worldwide atten-
tion as Roche lost a lawsuit for failing to
adequately warn physicians of the risk of
IBD. Subsequent lawsuits may have con-
tributed to Roche withdrawing Accutane
from the market in 2009. Currently, IBD
is listed as a possible adverse reaction of
isotretinoin in the package insert.
Before this issue’s article by Alhu-
sayen et al., the evidence beyond case
reports for a potential association
between IBD and isotretinoin consisted
of two reviews and two case–control
studies. In 2006, Reddy et al. (2006)
reviewed adverse reports from 1997 to
2002 registered with the voluntary FDA
MedWatch system and found 85 reports
of IBD associated with isotretinoin. Using
the Naranjo probability scale, the authors
determined that of these potentially asso-
ciated cases, 5% were highly probable
and 68% were probable. This study was
followed by a systematic review by
Crocket et al. (2009), which identified
12 case reports and 1 case series. Cases
varied in terms of lag time between iso-
tretinoin and IBD, duration of exposure,
dose of isotretinoin, and the specific mani-
festation of IBD. Using the Hill criteria to
evaluate causality, Crocket et al. (2009)
concluded that the evidence was insuffi-
cient to support a causal link between
isotretinoin and IBD. In their estimation, if
isotretinoin conferred no increased risk of
IBD, 59 cases would have been expected
among isotretinoin users in the United
States each year. Crockett et al. compared
this with FDA MedWatch reports, which,
although prone to underreporting, revea-
led only 14 cases of IBD in isotretinoin
users per year.
These reviews were followed by two
case–control studies. In 2009, Bernstein
et al. (2009) reported a population-based
case–control study using the Manitoba
IBD Epidemiology Database. The preva-
lence of IBD among controls was 1.1%,
and among isotretinoin users 1.2%. The
authors concluded that the evidence
did not support a link between IBD
and isotretinoin (Bernstein et al., 2009).
The following year, Crockett et al. (2010)
reviewed a US insurance claims database
and compared 8,189 cases of IBD with
21,832 matched controls. This study sug-
gested that isotretinoin use in the preced-
ing 12 months was associated with UC,
but not Crohn’s disease. The median
latency time between isotretinoin expo-
sure and UC diagnosis was 223 days,
and the median duration of exposure
was more than 2 months. Interestingly, a
positive dose–response relationship was
noted (Crockett et al., 2010). The authors
did note that although the odds ratio of
developing UC was high (4.36), the abso-
lute risk of developing UC was quite low.
(Popescu and Popescu (2011) followed
this with the estimation that 2,977
patients would need to be treated with
isotretinoin to result in one case of UC.
In sum, the evidence was contradic-
tory, with one case–control study suggest-
ing no relationship between isotretinoin
and IBD, and another suggesting an
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association between isotretinoin and UC,
but not Crohn’s disease. Neither study
controlled for acne severity or prior treat-
ment with antibiotics, and both differed in
terms of population, temporality, and
selection of controls. Thus, it is difficult
to know whether the differing results were
simply a consequence of study design.
In this issue, Alhusayen et al. add to
the literature on this subject. Alhusayen
et al. (2013) use comprehensive popula-
tion-based healthcare records of B4.5
million residents of British Columbia,
Canada, to help delineate the associa-
tion. They stratify analyses by age and
type of IBD, and adjust for oral anti-
biotic use and healthcare utilization.
Primary analysis showed no association
between IBD and isotretinoin. Prespeci-
fied secondary analysis among patients
12–19 years old revealed an association
between isotretinon and IBD; however,
a similar, but nonsignificant, correlation
was observed for topical acne medica-
tion and IBD. In addition, topical
acne medication, but not isotretinoin,
was associated with both UC and
increased risk of hospitalization for
IBD in secondary analyses. The authors
hypothesize that there is an association
between IBD and acne, but not with
isotretinoin (Alhusayen et al., 2013).
Is there a pathogenic mechanism that
could link isotretinoin and IBD? Is there a
pathogenic link between acne and IBD?
The mechanism by which isotretinoin
could induce IBD is unknown, but the
medication’s ability to stimulate natural
killer cells and apoptosis, regulate cyto-
kines, inhibit neutrophil chemotaxis,
differentiate B-cells, and alter glycoprotein
synthesis and epithelial tissue growth are
all speculated mechanisms (Crockett
et al., 2009; Alhusayen et al., 2013). It
is also plausible that isotretinoin could
help prevent IBD because of the ability of
retinoic acid to enhance barrier function,
inhibit proinflammatory Th-17 cells, and
upregulate T-regulatory cells (Crockett
et al., 2009). The latter may help explain
the consistent finding of odds ratios of less
than one for isotretinoin and CD in the
case–control study by Crockett et al.
(2010), and the finding that isotretinoin
was associated with fewer hospitaliza-
tions for IBD by Alhusayen et al. (2013).
Alternatively, impaired defense or hyper-
sensitivity response to bacterial patho-
gens, neutrophilic dysfunction, and cyto-
kine dysregulation may pathogenically
link IBD and acne.
Acne as a potential explanation for the
inconsistently posited association
between isotretinoin and IBD
Severe acne as a confounding variable
may help explain an apparent associa-
tion between IBD and isotretinoin.
Severe acne is a hyperinflammatory state,
and it may be associated with systemic
manifestations in SAPHO and PAPA
syndromes. SAPHO and pyoderma gang-
renosum are both known to be associa-
ted with IBD. Hidradenitis suppurativa
has also been shown to be associated
with acne and IBD. In addition, there
have been two case reports of acne
fulminans occurring in association with
IBD (Wakabayashi et al., 2011). In the
two case–control trials to date, only
Crockett et al. (2010) analyzed the
potential confounder of acne, and,
while they did not find an association,
acne severity was not assessed. In the
current study (Alhusayen et al., 2013),
the investigators concluded that their
findings reflected an association bet-
ween acne and IBD. The authors also
found an association between the use of
topical acne medications and IBD in two
subset analyses, and because topical
acne medications may serve as a surro-
gate marker for acne, the resulting
hypothesis that acne itself is associated
with IBD appears reasonable. Future
studies examining a link between acne
and IBD directly would be useful.
Oral antibiotics and IBD
Another potential confounder in the asso-
ciation between isotretinoin and IBD is
the use of oral antibiotics. Most patients
treated with isotretinoin have failed to
respond sufficiently to at least one course
of oral antibiotics, particularly in the
tetracycline class. Margolis et al. (2010)
reported an association between the
use of tetracycline antibiotics and IBD.
This association was the strongest for
doxycycline and Crohn’s disease. The
following year, Alikhan et al. (2011)
reviewed four questionnaire-based and
four population-based studies, and
found that all but one of these studies
supported an association between the
use of oral antibiotics and IBD. Neither
study evaluated acne as a confounder.
Alhusayen et al.’s current study is the first
to adjust for the use of tetracyclines and
erythromycin specifically. Both adjusted
and unadjusted rate ratios were reported,
and adjustment for antibiotic use, among
other factors, led to the mitigation or
nullification of positive associations
across all analyses (Alhusayen et al.,
2012). This supports the notion that con-
founders may explain the inconsistent
associations of isotretinoin with IBD.
Unique aspects of the current study
Previous literature on IBD and isotretinoin is
difficult to interpret. Alhusayen et al. were
the first to include a cohort using topical
acne treatment only, enabling an indirect
assessment of acne. The age range chosen
in this study is also unique. Although
previous case–control studies included
patients up to the age of 40 (Bernstein
et al., 2009) and X60 (Crockett et al.,
2010), Alhusayen et al. (2013) included
only patients aged 12–29 years old. As the
majority of isotretinoin prescriptions and
diagnoses of IBD occur in this age range,
the sensitivity of the analyses should be
strengthened. Sensitivity was also enhanced
in this study, as the authors required only
one ICD-9 code for IBD for diagnosis.
Secondary analysis using stricter criteria for
diagnosis did not alter the results.
Also worth noting is Alhusayen
et al.’s (2013) finding that topical acne
Clinical Implications
 A definitive link between isotretinoin and inflammatory bowel disease has
not yet been established.
 Potential confounders, such as acne and prior oral antibiotic use, may be
responsible for an apparent association between isotretinoin and inflam-
matory bowel disease.
 Current evidence suggests that isotretinoin does not increase the risk of
hospitalization for exacerbations of inflammatory bowel disease.
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medications, but not isotretinoin, were
associated with an increased risk of
hospitalization for IBD. This may reflect
closer patient–physician contact among
those taking isotretinoin, and thus earlier
diagnosis of IBD exacerbation and obvia-
tion of the need for hospitalization. This
finding does suggest that isotretinoin is
safe for use in patients with IBD, though
further studies are warranted.
Also of interest is that the authors allowed
cohort reentry after a 12-month period, as
long as patients did not have disqualifying
exposures in the previous year. The number
of patients accounting for more than one
observation is large (54,614 observations
among 46,922 unique patients in the iso-
tretinoin group; 239,144 among 184,824 in
the topical acne medication group; and
9,533,230 among 1,526,946 in the unex-
posed group). Although this adds uniformity
across all groups, the resulting data are only
true if the lag time between isotretinoin and
IBD is 1 year or less. For example, a patient
treated previously with isotretinoin could
constitute an observation in the unexposed
cohort, as long as a prescription for iso-
tretinoin had not been given in the previous
year. The authors chose this design because
the only case–control study revealing an
association between IBD and isotretinoin
(Crockett et al., 2010) assessed exposure
over 12 months before IBD diagnosis.
However, although not likely to exceed 1
year, the lag time between isotretinoin
exposure and development of IBD is
unknown, and Roche has lost lawsuits
for exposures occurring more than
12 months prior to the development of
IBD (http://www.drugwatch.com/accutane/
lawsuit.php). Therefore, we must interpret
the data of Alhusayen et al.’s study
cautiously, as it does not hold true if the
lag time between isotretinoin and IBD is
more than 1 year.
The final verdict
Although a final verdict has not been
reached, this study adds depth to our under-
standing of a possible link between isotreti-
noin and IBD. The findings support the idea
that acne itself may contribute to the
association observed between isotretinoin
and IBD, though this concept requires
additional study. Alhusayen et al. raise the
idea that any true association between
isotretinoin and IBD is likely to be strongest
within a younger age group, and that
isotretinoin is unlikely to exacerbate IBD.
A study directly analyzing a possible asso-
ciation between severe acne and IBD may
allow improved understanding of these data.
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Adaptive and Maladaptive Responses in
Skin: Mild Heat Exposure Protects
against UVB-induced Photoaging in Mice
Thomas Haarmann-Stemmann1, Fritz Boege2 and Jean Krutmann1
In this issue, Matsuda et al. demonstrate the protective effect of mild heat
preconditioning on UVB-induced photoaging in SKH-1 hairless mice. Mild heat
exposure stimulates the upregulation of HSP70 chaperones, which inhibit the
activities of matrix-degenerating enzymes, thereby avoiding wrinkle formation.
This newly identified heat-mediated process of adaptation to UVB radiation
exposure opens new opportunities to slow extrinsic skin aging.
Journal of Investigative Dermatology (2013) 133, 868–871. doi:10.1038/jid.2012.435
Induction of adaptive responses by low
levels of stress
Low levels of physical, chemical, or bio-
logical stress often allow a cell, tissue,
or organism to adapt and to improve its
resistance to subsequent stress exposure
at higher levels (Martins et al., 2011).
Such adaptive stress responses are
observed in all kingdoms of life and
with various types of stressors (radiation,
heavy metals, oxidants, alkylating
agents, and heat). They often display a
biphasic dose–response pattern, which
is typically not addressed by the classi-
cal threshold or linear non-threshold
models for dose–response relationships,
but by alternative mechanisms such
as hormesis, desensitization, or pre-
conditioning (Calabrese, 2004; Martins
et al., 2011). Prominent examples are
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